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Summary 
Transgenic mice that contain constructs of the Lmyc gene under the transcriptional  control of 
the immunoglobulin heavy chain enhancer (E/z) develop thymic hyperplasia and are predisposed 
to T cell lymphomas. Here we describe a second form of malignancy that occurs in aging Eg 
bmyc transgenic mice. The mean latency period for the development of this malignancy is longer 
compared with the E# I.-rayc T cell lymphomas but the overall incidence is increased threefold. 
The histopathological  morphology is that of a highly malignant mesenchymal neoplasm that 
closely resembles human fibrous histiocytoma. The tumor cells were classified as myelomonocytic 
on the basis of several lineage-specific  markers and the lack of rearrangements of the immunoglobulin 
heavy chain and the T cell receptor B loci. Cultured tumor cells produce macrophage colony- 
stimulating factor (M-CSF) protein and express the M-CSF receptor, suggesting the involvement 
of an autocrine loop in this malignancy. Similar to the Eg I.-m2/c T cell lymphomas, these tumors 
show high-level transgene expression but no detectable levels  of endogenous c-m  F mRNA, directly 
implicating the deregulated expression of bmyc in the generation of this malignancy. Eg bmyc 
myelomonocytic tumors show consistent trisomy of chromosome 16, implicating this as a secondary 
event in the development  of this tumor. In the light of recent findings that bmyc is expressed 
in human myeloid leukemias and in several human myeloid tumor cell lines, the results described 
here might implicate brayc in the development  of naturally occurring myeloid neoplasias. 
T 
he  myc  oncogene family  contains  three well-defined 
members: c-, N-, and L-myr. All three genes have a similar 
three-exon structure and encode nuclear phosphoproteins that 
contain several regions of extensive homology in their amino 
acid sequences (1). The conservation  of the individual myc 
genes through evolution suggests that they exert unique but 
related functions (2-6). Several studies have shown that myc 
gene products are involved in the regulation of cellular prolifer- 
ation and differentiation,  but their exact function remains 
to be elucidated (1). The COOH-terminal region of the c-, 
N-, and L-m,/:  proteins contains domains that have been shown 
to be functional for DNA binding and protein-protein inter- 
action in  transcription factors. Recently, a  specific DNA 
binding site has been identified for c-myc, suggesting that 
m  F  proteins  act as transcriptional  regulators  (7). 
While c-myc  is expressed in virtually all dividing cells, the 
expression of N- and brayr is more restricted and occurs pre- 
dominantly at earlier stages of development (8-10). Differential 
expression of myr family genes occurs in the development of 
lymphoid cells. The c-myc gene is expressed in all normal 
and transformed pre-B and B cells, as well as in plasma cells. 
N-myc expression is found in normal and transformed pre-B 
cells but expression is downregulated when pre-B cells differen- 
tiate into B cells and acquire surface receptors (8). Prelimi- 
nary data suggest a similar expression pattern in T cell devel- 
opment (R. DePinho, unpublished data). Lmyc expression 
has not been detected in lymphoid cells with the possible 
exception of very early precursors (DePinho et al., unpub- 
lished data). 
All three myc genes can cooperate with an activated Ha-ras 
gene to transform  primary rat embryo fibroblasts, but the 
bmyc gene has a lower transforming potential compared to 
c- and N-myc (5,  12-16). Activation  of the c-myc gene has 
been documented in a wide variety of naturally occurring 
tumors, but activation of the other two mF: genes has been 
found only in a more restricted set of malignancies (17). N-myc 
activation is found in tumors of neuroectodermal origin (2, 
18-21), in T cell lymphomas (22, 23), and most recently in 
Hepatitis B virus-associated  hepatocellular carcinoma (24). 
In naturally occurring tumors, L-m'/c  activation has been clearly 
implicated only in a subset of small cell lung carcinomas (20). 
However, both N- and I,  myc are expressed in different subsets 
of human acute myeloid leukemias and myeloid tumor cell 
lines (11). 
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control of the Ig enhancer element (E#) have been introduced 
into the germline of transgenic mice. The results obtained 
showed common as well as unique activities (25-32).  E/~ 
N-myr and E# c-myc transgenic mice are similarly predisposed 
to the development of pre-B and B cell lymphomas (25-30). 
However, the onset of E# N-myc tumors was delayed com- 
pared with the onset of E# c-myc tumors (28, 29). Mice that 
received an Eg L-myc construct virtually identical in its de- 
sign to the E# c- and N-myc constructs had features quite 
different from the E# c- and N-myc animals (31). Expression 
of the transgene was predominant in pre-T and T  cells, and 
was accompanied by disturbances of thymic architecture and 
high level expression  of the early T  cell marker 1Cll (31). 
Eg bmyr transgenic mice are predisposed to the development 
of lymphomas (predominantly thymic T  cell tumors), but 
with a lower incidence and a much longer latency period than 
E# c- or N-myc transgenics (31). Here we report that E# 
L-myc transgenic animals develop a second, distinct form of 
malignancy later in life that occurs with a higher frequency 
than the T  cell tumors and apparently originates from my- 
elomonocytic and not from lymphoid cells. 
Materials  and Methods 
Molecular Analyses and Probes.  Preparation  of genomic DNA 
from tumor samples and cell lines was performed as previously  de- 
scribed (33). DNA blotting procedures were performed  as described 
elsewhere (34, 35). The J, probe used for Southern analysis is a 
2-kb fragment covering J. 1-4 (36, 37), the J.E#-  probe is an 
XbaI-EcoKI fragment covering  J.3-4, the J~2 probe that was used 
to detect TCK-B rearrangements is a 1.9-kb HindIII-BamHI frag- 
ment containing the J~ locus (38), and the cg probe is described 
in Lewis et al. (39). Preparation of KNA and Northern blotting 
was as described  (33). c-, hi-, and b,nyc probes and the probes specific 
for C# and VhJ558 have already been described (3, 8, 14, 35, 40). 
The Thy-1 probe is a 1.4-kb ApaI fragment isolated from the 3' 
untranslated region of  the Thy-1 gene (41), thetis probe is a 1.3-kb 
fragment from the plasmid pros 1 (42). The c-myb probe is a 2.5- 
kb EcoKI c-DNA fragment (43), the c-f  ms probe is a 3.6-kb frag- 
ment from the murine c-DNA (44), the macrophage (M)1-CSF 
specific probe is a 1.8-kb fragment from the murine c-DNA, and 
the probe specific  for granulocytdmacrophage (GM)-CSF is a 1-kb 
fragment from the murine cDNA. 
Tissue Culture Conditions.  Single  cell suspensions prepared from 
primary tumor samples obtained at the time of  autopsy  were grown 
at different cell densities in KPMI with 20% FCS, 2 mM L-glu- 
tamine, with or without 50 mM 2-ME, and antibiotics. Ceils were 
passaged using Trypsin/El~A. To assay  for M-CSF activity in cul- 
ture supematants of tumor cells, bone marrow was harvested  from 
femurs of C57BI6 mice and plated in 1 ml 1% semisolid agar at 
a density of 10  s cells per 35-mm culture dish (45). 200 gl of su- 
pernatant from each control cell line or from tumor cell cultures 
or 250 U of purified M-CSF were added to the medium. After 
an incubation period of 6 d, colonies were enumerated and stained 
with Giemsa solution for morphological analysis. The assay for 
1  Abbreviation  used  in this  paper:  GM-CSF, granulocyte/macrophage  colony- 
stimulating factor. 
phagocytosis  was done as described (48). Briefly,  the cells were in- 
cubated in medium with 3-ram latex beads for 16 h, washed three 
times while still adhering to the plate, trypsinized, pelleted onto 
glass slides, and examined microscopically. 
Antibody Staining Procedures.  Single  cell suspensions were made 
at the time of autopsy from tumor tissue in RPMI supplemented 
with 5% FCS. Cells were filtered through a cushion of 2 ml of 
FCS, washed in staining solution (PBS, 1% BSA, 0.1% sodium 
azide), and incubated on ice for 30 rain with either directly FITC- 
conjugated antibodies or with biotin-labeled  antibodies. Cells were 
washed twice in staining solution after the incubation and if  neces- 
sary counterstained with FITC- or PE-labeled streptavidin and ex- 
amined under  a fluorescence microscope. Frozen sections were 
manipulated in a humid chamber at room temperature. They were 
blocked in PBS/1% BSA for 30 min, washed three times with PBS, 
incubated with biotinylated antibody in PBS/1% BSA for 30 min, 
again washed three times in PBS, stained with FITC-coupled strep- 
tavidin, washed, mounted, and examined  under a fluorescence  mi- 
croscope. 
Detection of  M2/eloperoxidase  and Nonspecific  Esterase  Activity.  1Le- 
agents to perform tests for mydoperoxidase and naphthyl acetate 
esterase were purchased as a kit (Sigma Chemical Co.). To obtain 
cytosmears, ceUs from tumor cultures or directly explanted from 
tumor tissue were pelleted onto glass slides, fixed, and treated ac- 
cording to the manufacturer's  instructions. Frozen sections  of tumor 
tissue were also used in the naphthyl acetate assay  and were treated 
in the same way as the cytosmears. After the procedure the glass 
slides were counterstained with hematoxylin/eosin, mounted, and 
examined microscopically. 
Histological Evaluation.  Tissues were fixed in  10%  neutral 
buffered  formalin, embedded  in para~n, sectioned,  and stained  with 
hematoxylin eosin. Cytosmear preparations were fixed in meth- 
anol and stained with Giemsa/White stain. 
Chromosome  Preparation.  Metaphase  spreads were prepared from 
cell suspensions of subcutaneous solid tumors, spleen, mesenteric, 
and peripheral lymph nodes. The metaphase plates were G-banded 
according to a slightly modified  method of Wang and Fedoroff  (58, 
59). Between 6 and 10 metaphase plates were karyotyped for each 
individual tumor.  Duplicated chromosomes 16  were identified 
microscopically  in 5-10 plates of high banding quality. Chromo- 
somes were identified  according  to the criteria specified  by the Com- 
mittee of Standardized Nomenclature (47). 
Results 
Mesenchymal  Tumors in E#  l_,myc Transgenic Mice.  The 
generation and establishment of E# L-rnyc transgenic mouse 
lines with various constructs and the tissue-specific expres- 
sion pattern of the transgenes has been described (31), Of 
a population of E# I.-myc transgenic mice observed over a 
period of 18 mo, ,x,10% developed T cell lymphomas with 
an average latency of 9 mo (31). A distinct second form of 
malignancy occurs in older transgenics.  Of a population of 
91 Eg L-myc mice, "~30% developed  these neoplasms with 
an average latency of 14 mo (Table 1). These tumors were 
manifest as solid tumors arising either in the skin or in the 
peritoneal cavity. Histopathological evaluation showed highly 
invasive masses of malignant mesenchymal cells with a ten- 
dency to form giant cells (Fig.  1, a and b). These malignan- 
cies most closely resembled malignant fibrous histiocytoma 
and arose in seven of nine E# l.-rnyc transgenic lines  with 
the highest incidence in the line EVLcd 31.14 (Table 1). 
314  Myelomonocytic  Tumors in E# L-myc  Transgenic Mice Table  1.  Mesenchymal Tumors in E/~ L-myc Transgenic Mice 
No.  of 
Line  Animals  Tumor  Location  Age 
EL  27.3  26  27.3 
273.20.8 
273.25 
273.36.13 
273.23.7 
273.39 
29.7  8  - 
35.6  18  356.21.15 
EVL  18.1  7  181.26 
181.21.15 
181.FG.7 
20.14  2  215.5.9 
EVL,d 31.14  15  314.10.10 
314.10.1 
314.10.15 
314.10.9 
314.10.12 
314.10.13 
314.23 
314.10 
314.5 
314.8 
314.14 
31.14 
314.33 
314.21.7 
314.21.4 
33.42  6  342.10 
342.13.5 
342.12.19 
342.13.8.15 
42.12  9  42.12 
Total  91  31 
Skin 
Int/Spl/Skin 
Skin 
Skin 
Skin 
Spl/LN/Kidney 
Int/Skull 
Skin/LN 
Skin 
Skin/Head 
Skin/lnt 
Skin 
Skin/Head 
Skin/Head 
Skin 
Skin 
Skin/Head 
Skin 
Skin 
Skin 
Skin 
Skm 
Skin 
Skin 
Skin 
Skin/Head 
LN/Spl/Skin 
Skin/Muscle 
Skin 
Skin/Head 
Skin 
m0 
17 
10 
14 
13 
13 
16 
14 
6 
13 
11 
15 
12 
16 
14 
14 
12 
14 
12 
12 
17 
13 
16 
18 
17 
13 
15 
11 
13 
11 
14 
23 
Representation of all mesenchymal tumors that arose in a population of 
91 E/~ L-myc transgenic mice. No tumors were observed during a time 
period of 18 mo in a population of 50 nontransgenic littermates. 
Average time of tumor onset was 14 mo. lnt, intestinal cavity; Spl, spleen; 
LN, lymph node. 
Cells explanted from these tumors were usually not adapt- 
able to tissue culture conditions  and could be kept only for 
two or three passages, with the exception of the tumor 314.8, 
where >20 passages were achieved (Table 2). In three of five 
cases tested, tumors were transplantable into syngeneic animals 
(Table 2). The transplantability was tested using cells directly 
Table  2.  Cell  Explants of Myelomonocytic Tumors 
Tumor  Growth"  Transplant*  MPOS  Phagocytosisl 
EL  273.23.7  +/-  -  +  + 
273.39  +  +  +  +  + 
EVL  214.5.9  +/-  -  +  + 
181.26  +/-  ND  +/-  ND 
EVLcd  314.8  +  +  +  +  +  +  + 
314.14  +/-  +  +  + 
" Growth of cells obtained from tumor tissue according to their approx- 
imate doubling time.  + + +, cells were split 1:3 after 3-4 d;  +, cells 
were split 1:3 after 8-10 d;  +/-,  cells were split after 2-3 wk. 
t 1-1.5 ml of cultured tumor cells were injected at a density of 106-10  ~ 
cells/ml intraperitoneally and subcutaneously into  syngeneic animals. 
s + / -, low;  +, medium;  + +, high intensity of staining with a sub- 
strate specific for myeloperoxidase (Sigma Chemical Co., St. Louis). 
II All tumor cells showed approximately the same degree of phagocytic 
activity. In the case of 214.5.9, only 50% of the cells showed phagocytic 
activity. The negative controls for the phagocytosis  assay  were 38B9 pre-B 
cells and NIH 3T3 fibroblasts. 
obtained at autopsy of the animals. For the tumor 314.8, cells 
were  also  successfully  transplanted  after tisshe  culture. 
Mesenchymal Tumors in EI~ L-myc Transgenic Mice Consist 
of  Myelomonocytic and Not of  Lymphoid Cells.  To identify the 
exact cell type of these mesenchymal  tumors,  several lym- 
phoid lineage markers were first tested. Southern analysis of 
DNA from mesenchymal tumors revealed no rearrangements 
of the Ig/~ heavy, the Igx light  chain locus,  or the TCR 3 
locus (Table 3). We did not detect transcripts specific for the 
T  cell surface marker Thy-1 (Fig. 2), the TCR c~ or 3, genes, 
or the lymphoid cell-specific enzyme TdT (not shown). How- 
ever, transcripts  hybridizing to an Ig constant region (C/z)- 
specific probe were found in the control T  cell tumor 181.6 
and  in  all mesenchymal tumors,  except  tumor  273.25  and 
342.10.  These transcripts correspond in size (2.2 and 2.6 kb) 
to germline C/~ transcripts (40) (Fig. 2). A major C/z-specific 
transcript of 2.4 kb, corresponding to a mature C/z mRNA, 
was detected in the control B cell tumor 356.3. and in tumors 
273.25 and 342.10 (Fig. 2). Rehybridization of the same blot 
with an Ig c-K probe showed the absence of Ig K light chain 
messenger RNA in all tumors except 273.25 and 342.10 (Fig. 
2). Material from tumor 273.25 was no longer available, but 
a histopathological reevaluation of tumor 342.10 showed the 
presence of both lymphoid and mesenchymal malignancies. 
It is likely that  the  mature  Ig/~ and  Ig x  transcripts  seen 
in both cases stem from lymphoid tumor cells contaminating 
the mesenchymal tumor (not shown).  342.10 tumor cells in 
culture failed, however, to produce a nonadherent lymphoid 
cell population,  arguing  that in  this case mature  C/~  tran- 
scripts and, therefore, Ig rearrangements could be carried by 
the mesenchymal cells.  However,  the absence of mature Ig 
/z heavy and Ig K light chain messenger RNA  and the lack 
of Ig and TCR gene rearrangements in the majority of the 
315  M6r6y et al. Figure 1.  (A) Skeletal  muscle in- 
vaded by mesencbymal tumor cells 
stained with hematoxylin/eosin. (B) 
Formation of tumor giant cells in 
a paraffin section of tumor tissue 
stained  with hematoxylin/eosin. (C) 
Cytosmear  of tumor cells colored 
with Giemsa/White  stain. (/9) Calls 
after reaction with substrates  specific 
for naphthyl acetate esterase or (E) 
myeloperoxidase. (F) Cells after in- 
cubation with 3.5-mm latex beads. 
The cells shown in C, D, E, and 
F were from tumor 314.8. Positive 
controls  for the myeloperoxidase- 
and  naphthyl-specific esterase as- 
say were neutrophils  from blood- 
smears, cytosmears  from the my~loid 
cell lines RAW, P338, and MIS2. 
Negative controls  consisted of cy- 
tosmears  from  the  Abelson  line 
38B9,  NIH3T3 fibroblasts, and a 
frozen  section  of a  thymic  lym- 
phoma derived from an E# brayc 
transgenic animal. 
cases dearly classifies the E# b.rayc mesenchymal tumors as 
nonlymphoid. 
Giemsa-stained  cytosmears  from  explanted  tumor cells 
showed a morphology consistent with monocytes and macro- 
phages (Fig. 1 C). A number of assays specific  for myelomono- 
cytic cells were performed: all tumors showed phagocytic ac- 
tivity,  the  presence  of myeloperoxidase,  naphthyl-specific 
esterase, and expression  of the surface marker Mac-1  (Fig. 
1, and Tables 2 and 3). The cells derived from meseuchymal 
neoplasms that arise in aging E# bmyc transgenic animals 
were therefore classified as myelomonocytic. 
Oncogenes  and Growth  Factors.  The nuclear proto-oncogenes 
c-rayb and c-los are expressed at different stages during the 
development of lymphoid and myeloid cells; c-myb transcripts 
are easily detected in pre-B calls and myeloid precursor cells, 
but expression  is downregulated in mature lymphoid cells 
and during terminal myeloid differentiation. The c-fos gene 
is expressed at high levels in mature myeloid cells but is not 
readily detected in lymphoid calls (46, 48-50). To investigate 
the expression pattern of c-myb and c-fos in E# L-myc lym- 
phoid and myelomonocytic  tumors, KNA from both tumor 
types was analyzed by Northern blotting. Levels of c-myb- 
specific RNA are high in the E# bmyc lymphoid tumors com- 
pared with 38B9 pre-B cells with the exception of the tumor 
356.3, a mature B cell tumor and tumor 342.10, which might 
represent a mixture of myelomonocytic  and lymphoid tumor 
cells. The level of c-fis message is low to undetectable (Fig. 
3 B). Compared with the same set of controls, the reverse 
situation is found for the myelomonocytic  tumors, i.e., very 
low levels of c-myb and high levels of c-)~s expression  (Fig. 
3 A). A similar inverse correlation of c-myb and c-Jos expres- 
sion between lymphoid and myeloid tumor cells has been 
reported (46),  and most probably reflects the lineage com- 
mitment and differentiation stage of the tumor cells. This 
again points to the myeloid origin of the mesenchymal E# 
bmyc tumors. 
To investigate the possibility that myeloid/granulocyte- 
specific growth factors or receptors are expressed in E# bmyc 
myelomonocytic  tumors and may have contributed to the es- 
tablishment of these neoplasias, KNA from fresh tumor tissue 
was analyzed for the expression of M-CSF, G-CSF, GM-CSF, 
Ib3, and the M-CSF receptor c-f  ms. Expression of c-f  ms was 
detected in all myelomonocytic  tumors (Fig. 3 A). Transcripts 
specific for II.-3 and G-CSF were not readily detected in the 
myelomonocytic tumors, but transcripts for GM-CSF were 
found in tumor 214.5.9  (Fig.  3 A).  Expression of M-CSF 
was found in most of the myelomonocytic tumors (Fig.  3 
A). The sizes of the M-CSF transcripts are 1.6 and 4 kb cot- 
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Markers 
Tumor  NSE*  Mac-l*  Jhr  s  gr  s  J~2rS 
EL 
EVL 
EVLcd 
273.25  ND  ND  -  - 
273.23.7  + + +  +  -  - 
273.39  + + +  +  -  - 
215.5.9  + +  +  -  - 
181.26  +  +  +  -  - 
314.10.13  + +  +  -  - 
314.23  +/-  +  -  - 
314.5  +  +  -  - 
314.8  + +  +  -  - 
314.14  + +  +  -  - 
31.14  ND  +  -  - 
314.33  ND  +  -  - 
314.21.7  + + +  +  -  ND 
342.10  + + +  +  -  ND 
342.12.19  + + +  +  -  ND 
* The assay for naphthyl acetate esterase was performed either with cells 
directly explanted from a tumor and pelleted onto glass slides or by using 
sections of frozen tumor tissue according to the fnanufacturer's protocol 
(Sigma Chemical  Co.). 
* Staining of tumor cells with Mac-1 was carried out on cytosmears or 
on cells in suspension. The percentage of Mac-l-positive cells was 80% 
for the tumor 273.39, 75% for 273.23.7,  76% for 314.10.13, 90% for 
214.5.9, >95% for 314.5, >95% for 314.8, 90% for 31.14, 84% for 314.14, 
43% for 314.21.7, and 85% for 314.33. In all other cases the staining 
was done on frozen sections of tumor tissue, and was not quantified. 
S  Jhr,  Kr, J~2r: rearrangements  of the J region of the heavy chain locus, 
the g light chain locus, and the T  cell receptor fl locus, respectively. 
responding to alternative splicing (51). Both messages were 
found in tumor 342.10 but only the 4-kb message was de- 
tected in all other tumors (Fig.  3 A). 
The presence and activity of  M-CSF protein was also tested 
in supernatants of four different myelomonocytic  tumor cell 
cultures by assaying the outgrowth of macrophages from 
normal bone marrow. Freshly aspirated  bone marrow cells 
were treated with supernatant from a tumor cell culture or 
the appropriate controls. The supernatants from three of four 
tumor cell cultures produced colonies that exclusively dis- 
played macrophage morphology (Table 4), indicating that they 
produce functional M-CSF. The supernatant from tumor cell 
culture 215.5.9 produced 50% macrophage colonies and 50% 
granulocyte colonies (Table 4), showing that tumor 214.5.9 
secretes both functional GM-CSF and M-CSF. The lymphoid 
control cell line 38B9 did not yield colonies, but all the my- 
eloid control cell lines did provoke the outgrowth of either 
macrophage, granulocyte, or mixed colonies, demonstrating 
their production of either M-CSF or GM-CSF (Table 4). 
Karyotypic Abnormalities in El~ ~rayc Tumors.  Four my- 
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Figure 2,  Northern analysis  of 10 #g total RNA derived from E/~ bm,/c 
myelomonocytic tumors and controls. Duplicate blots were sequentially 
hybridized with the indicated probes. To control for uniform loading, the 
blots were probed with a GAPDH-specific DNA fragment.  From left to 
right were LTK-  fibroblasts,  the myeloid cell lines J774,  MIS2,  and 
M1/MT, a T cell and a B cell lymphoma derived from E/~ L-m?c trans- 
genics (181.6 [T] and 356.2 [B] respectively),  and nine  different myelomono- 
cytic tumors that arose in E/~ bmyc transgenic mice. The second panel 
from the top represents a longer exposure of the first panel. 
elomonocytic tumors (nos.  I-4, Table 5),  two lymphomas 
(nos. 5 and 6), and one plasmacytoma (no. 7) that developed 
in the E/~ bmyc transgenic lines 31.14, 27.3, 29.7, 42.12, and 
18.1 were karyotyped (Table 5). A trisomy of chromosome 
16 was observed in all four mydomonocytic  tumors as a single 
and consistent chromosomal aberration  (Table  5,  Fig.  4). 
Trisomy 15 was a nonrandom chromosomal change in the 
lymphomas nos. 5 and 6. Trisomy 16 was also observed in 
lymphoma no. 5. The plasmacytoma (no. 7) showed trisomy 
of chromosome 9 and a translocation of chromosomes 14 and 
X  (Table 5).  Since all were primary tumors, the likelihood 
of secondary chromosomal change was minimal. This is also 
reflected by the absence or very low frequency of  chromosomal 
rearrangements (marker chromosomes) in all seven tumors 
and also by their strict modal chromosome nos. 41 and 42, 
respectively  (Table 5). 
Downregulation of c-myc Expression in Myelomonocytic Tu- 
mors.  A downmodulation of the expression of endogenous 
myc genes has invariably been observed in tumors that con- 
tain activated myc genes or transcriptionally deregulated myc 
transgenes (17, 21, 25, 28, 29,  31). For c-m  F, this effect is 
achieved by the deregulation of its expression alone; in the 
case of N- and bmyc, a high level of expression may also be 
necessary  for the downmodulation of endogenous myc ex- 
pression (25, 28, 29, 31, 52). All E/~ L-myc  myelomonocytic 
tumors described here produce levels of bmyr mRNA that 
are comparable to the levels expressed in E/~ L-myc  lymphoid Figure 3.  (.4)  Expression of c-rayb, c-fos, c-f  ms, M-CSF, and GM-CSF in E/z bra?r myelomonocytic tumors and controls. EN 8.4 is a B cell tumor 
derived from a E# N-myc transgenic animal; A19 and A20 represent RNA samples from LPS-stimulated splenocytes~ Duplicate blots were prepared 
with 10/zg of total RNA from the indicated source per lane. RNA loading was controlled by hybridization with GAPDH. (B) Duplicate blots showing 
expression of c-ra?b and c-Jbs in E/~ L-rayc  lymphoid tumors and controls. The last hybridization was performed with the GAPDH probe to ensure 
uniform loading. 
Table  4.  Production  of M-CSF in Myelomonocytic Tumors 
Colony morphology* 
CFU/10 s cells/  Mac/Gran 
Supernatant  0.2  ml SN*  Mac  Gran  mix 
Controls:S 
Medium  0 
38B9  0 
J774  109  +  2  82  7 
MIS2  1  +  1  100 
P388  8  +  3  100 
WD/pLJ  48  +  2  65  6 
M-CSF  (250U)  47  _+  4  100 
Tumor cells: 
314.8  15  +  8  100 
181.26  8  +  2  100 
214.5.9  7  +  1  50  50 
273.23.7  6  +  1  100 
11 
29 
* The numbers indicate the percentage of colonies that consist of macro- 
phages or granulocytes or the percentage of colonies that show a mix- 
ture of both cell types. 
Given are the numbers of CFU developed after the treatment  of nor- 
mal murine bone marrow cells plated at a density of 10  s per 35-mm dish 
in semisolid agar with 200/LI of supernatant of the indicated cell lines. 
S 38B9 is an  Abelson virus-transformed  pre-B cell line, J774,  M1S2, 
P388, and WD/pLJ are myeloid control  cell lines. 
tumors (Figs. 2 and 5). As there is no endogenous L-myc ex- 
pression in normal murine lymphoid or myeloid cells, in- 
cluding macrophages and their precursors (8, 31, and T. M6r6y 
and P. E. Fisher, unpublished results),  a third exon murine 
bmyc probe was used to detect expression from the E/z L-myc 
transgene,  c-myc mRNA  is  undetectable  in  E/~  l:myc my- 
elomonocytic tumors  (Fig.  5).  This downregulation  of en- 
dogenous c-myc expression has also been observed in E/~ l,-myr 
lymphomas (31)  and  implicates  the deregulated  expression 
of l:myc directly  in  the  tumorigenic  process. 
Discussion 
Myelomonocytic  Tumors in Elz Lmyc  Transgenic Mice.  Elz 
bmyc transgenic mice are predisposed to T  cell lymphomas, 
but later develop a second form of neoplasia diagnosed as malig- 
nant  fibrous histiocytoma.  These malignancies  occur  with 
a high incidence  (31%) in E/~ I.-myc transgenic mice after a 
mean latency period of 14 mo. The tumor cells were classified 
as mydomonocytic and nonlymphoid on the basis of a number 
of lineage-specific markers. The expression patterns of c-myb 
and c-fis in these tumors correlate inversely with the pattern 
found  in E# I.-myr lymphoid tumors  and  are characteristic 
of more mature  myelomonocytic cells  (46). 
Histiocytic or monocytic sarcomas have already been de- 
scribed to occur in mice and were then classified according 
to morphological features. The tumor infiltrate in these sar- 
comas contained giant calls that were also observed to occur 
in the E/~ Lmyc tumors. More recently, histiocytic lymphomas 
were found in transgenic mice that contain an activated N-ras 
gene under the transcriptional control of the Ig heavy chain 
enhancer and the SV40 promotor (53).  The tumor cells dis- 
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Figure  4.  Chromosomal configuration  of E/~ I:myr myelomonocytic 
tumor cells  (tumor no.  3). 
play the Mac-1 antigen on their surface, but in contrast to 
the E# L-myc  malignancies, do not show phagocytic activity 
or form  giant cells (53).  These  tumors  were classified as a 
reticulum cell sarcoma type A (53). Similar to the E# L-myc 
transgenic mice, E#SV N-ras animals also develop thymic T 
cell lymphomas  that occur with a lower incidence than the 
myeloid  tumors  (53). 
Other cases of monocyte/macrophage tumors were observed 
in BALB/c mice at very high frequency when infected with 
a c-myc-containing retrovirus and treated with pristane (54). 
In some cases retroviral insertion upstream of the M-CSF gene 
activated the production of M-CSF. As the tumor cells bear 
the M-CSF receptor (of  ms), an autocrine loop was installed 
and permitted indefinite growth (54,  55).  We have demon- 
strated the expression of the M-CSF receptor (c-f  ms) and the 
presence of functional M-CSF in E# L-myc  myelomonocytic 
tumors.  It is therefore not unlikely that a similar autocrine 
mechanism  is  responsible  for  the  full  transformation  and 
growth  of these  tumor cells. However,  further studies of 
Figure  5.  Comparison  of the levels of expression  of L-rayc and c-myc 
in E/~ L-rayc myelomonocytic tumors and control cells by Northern anal- 
ysis of 10/~g of total RNA from the indicated  sources (as in Fig. 3 A). 
Duplicate  blots were prepared and controlled  for uniform loading by re- 
hybridization  with  a GAPDH-specific  probe  (not shown). growth interference with anti-M-CSF antibodies are neces- 
sary to show the existence of an autocrine loop in E# brnyc 
myelomonocytic tumors. 
Incidence  and Latency  Period  of  E# L.myc Malignancies.  One 
of the most striking features of E# I:myc myelomonocytic 
tumors is their increased latency period. The mean age at 
which transgenic mice develop this malignancy is 14 mo com- 
pared with 9 mo for the development of lymphoma (31). 
One explanation for this phenomenon could be that im- 
munosurveiUance is impaired in older mice and that this effect 
is even exacerbated by the expression of an L-myc transgene 
in lymphoid cells. Age-associated thymic atrophy in humans 
is bdieved to be responsible  for senescence of the immune 
system and subsequent development of autoantibodies and 
tumors (56).  However,  one would also expect the number 
of T  cell lymphomas to rise. 
As the tumorigenic process is a multistep phenomenon, 
it is also conceivable  that additional steps leading to my- 
elomonocytic tumors occur rarely in younger animals but 
are more frequent in older mice. This would explain a longer 
latency  as well as a higher tumor incidence in later life. 
It has been shown that in some circumstances the number 
of myeloid ceils, especially the macrophage population, rises 
and the lymphoid population decreases in aging animals. Such 
a scenario could provide more myeloid than lymphoid target 
ceils for transformation by the I.,myc transgene and could also 
increase the occurrence of random secondary events that are 
necessary in the tumor formation process thereby leading to 
a higher number of myelomonocytic  tumors in older animals. 
Another major difference between E# L-myc  lymphoid and 
myelomonocytic  tumors is the correlation of their incidence 
with transgene copy number. E# L-rayc,  like E# N-myc, lym- 
phoid neoplasms arise with the highest incidence in high- 
copy number lines (>10 copies) (28, 31), but E# L-myc my- 
elomonocytic tumors do not show such a correlation. The 
highest incidence is observed in the line 31.14, a low-copy 
number line.  Animals from this line show all the prelym- 
phomatous features typical for E/~ L-myc  transgenics, but have 
so far failed to devdop lymphoma (31). 
Cellular Origin of E# Lmyc Myelomonocytic Tumors.  The 
original cell type that has undergone transformation-related 
changes and given rise to the myelomonocytic  tumors in E# 
bmyr transgenic mice is not easily identified. Several lineage- 
specific markers classify the tumor cells as myelomonocytic. 
However,  the activity of the Ig enhancer and the presence 
of germline C# transcripts could be consistent with early 
lymphoid cells, e.g., a pre-B cell precursor,  or a bipotential 
myeloid/lymphoid precursor call that differentiated during 
or after the transformation into a myelomonocytic cell It 
has been reported that the transfection of tumorigenic pre-B 
cells with v-tar or the infection of normal pre-B cells from 
long-term bone marrow cultures with fins can force pre-B 
cells to undergo lineage switch and to differentiate into mac- 
rophages (48, 57), suggesting that the commitment of pre-B 
cells to the lymphoid lineage is not absolute and lineage switch 
can be induced by external stimuli. Considering that expres- 
sion of the E# L-myc transgene was not detected in normal 
macrophages from bone marrow and peritoneum (T. M6r6y, 
unpublished results) but was detected in lymphoid cells, in- 
cluding pre-B cells (31, and T. M6r6y, unpublished results), 
it is conceivable that the myelomonocytic tumors observed 
in E# L-myc transgenics originate from a transformed early 
lymphoid precursor that has undergone a lineage switch during 
later stages of differentiation. 
ChromosomaI  Aberrations in E# L-myc Tumors.  Trisomy 16 
occurs systematically and in a nonrandom fashion in E# l_,myc 
myelomonocytic  tumors, suggesting that this chromosomal 
aberration represents a second step in the generation of my- 
elomonocytic malignancies. It is conceivable that chromo- 
some 16 carries one or several genes that are involved either 
in the early transformation events or in later stages of tumor 
progression. Previous genetic studies have revealed trisomy 
of chromosome 15 in murine T and B cell lymphomas and 
erythroleukemias irrespective of the inducing agent (58-60). 
In these cases it has been suggested that the chromosomal 
imbalance was a late event in tumorigenesis and is associated 
with the progression of the tumor rather than with its initi- 
ation (61). It is very likely that the same situation applies 
to the E# L-myc myelomonocytic  tumors, but further studies 
are needed to identify the elements of chromosome 16 respon- 
sible for such an enhancement of tumor progression. 
Downmodulation  of  Endogenous  c-myc  Expression.  The down- 
modulation of the endogenous myc gene expression in tumors 
in which one member of the myc family genes is activated 
is well documented (21, 25, 27-29). Expression of the L-myc 
gene is efficient in crossregulating c- and N-myc expression 
in lymphoid tumors (31). The absence of c-myc expression 
in E# bmyc myelomonocytic  tumors is consistent with these 
findings and implicates the transcriptionally deregulated L-myr 
gene directly in the tumor formation process. The exact mech- 
anism by which crossregulation of rnyc gene expression  is 
achieved remains speculative. It is clear, however, that high 
level expression of one myc family member alone is insufficient. 
For example, coordinate high level expression of c- and N-myc 
does occur in Abdson-transformed pre-B cell lines derived 
from E# N-myc transgenic mice, but no endogenous c-my 
expression is detected in spontaneously arising E# N-myc pre-B 
cell tumors (52). Thus, crossregulation of myc genes in a trans- 
formed cell can only be achieved if one member of the rnyc 
family is causally implicated in the transformation process. 
L-myc is expressed in the mouse monocyte precursor line 
M1S2 (Fig. 1), but also in human myeloid leukemias and in 
a subset of human myeloid tumor cell lines (11). In addition, 
L-myc is clearly capable of predisposing transgenic animals 
to the development of myelomonocytic tumors. It is there- 
fore conceivable that I.-rnyc  plays a pivotal role in the develop- 
ment of at least a subset  of myeloid tumors. 
320  Mydomonocytic  Tumors  in E# bmyc Transgenic Mice We are indebted to Connie Gee for providing us with the myeloid cell lines J774, M1S2, and M1/MT; 
Alan Stall for providing anti-Mac-1 and anti-B220 antibodies; Richard Stanley for the mouse c-f  ms probe; 
and Clive Wood (Genetics Institute)  for M-CSF- and GM-CSF-specific probes. 
This work was supported by the Howard Hughes Medical Institute  (HHMI) and National Institutes of 
Health grants  AI-20047, CA-42335, and CA-23767. T. Mrrry and G. Lee are fellows of the HHMI. 
Address correspondence to Frederick W. Alt, Howard Hughes Medical Institute Research Laboratories, 
Columbia University College of Physicians and Surgeons, 701 West 168th Street, New York, NY 10032. 
Received for publication  19June  1991  and in  revised form  30 September  1991. 
References 
1.  Zimmerman,  K., and F.W. Alt.  1990. Expression and func- 
tion of myc family genes. CRC Crit. Rev. Oncogenesis. 2:75. 
2.  Kohl, N., C. Gee, and F. Alt.  1984. Activated expression of 
the N-myc gene in human neuroblastomas and related tumors. 
Science (Wash. DC).  226:1335. 
3.  Legouy, E., R. DePinho, K. Zimmerman, R. Collum, G. Yan- 
copoulos, L. Mitsock,  R. Kriz, and F. Alt.  1987. Structure 
and expression of the murine L-myc gene. EMBO (Eur. Mol. 
Biol. Organ.) f  6:3359. 
4.  Stanton, L., M. Schwab, and M. Bishop. 1986. Nucleotide se- 
quence of the human N-myc gene. Proc. Natl. Acad. Sci. USA. 
83:1772. 
5.  DePinho, K., K. Hatton, A. Tesfaye, G. Yancopoulos, and F. 
Alt. 1987. The human myc gene family: structure and activity 
of L-myc and an bmyc pseudogene. Genes & D~.  8:1311. 
6.  Kaye, F., J. Battey, M. Nau, B. Brooks, E. Seifter,  J. DeGreve, 
M. Birrer, E. Sausville, and J. Minna. 1988. Structure and ex- 
pression of the human bmyc gene reveals a complex pattern 
of alternative mRNA processing. Mol.  Cell. Biol. 8:186. 
7.  Blackwell, K., L. Kretzner, E. Blackwood, R.N. Eisenmann, 
and H. Weintraub. 1990. Sequence specific DNA binding by 
the c-myc protein.  Science (Wash. DC).  250:1149. 
8.  Zimmerman,  K., G. Yancopoulos, R. Collum, R. Smith, N. 
Kohl, K. Denis, M. Nau, O. Witte, D. Toran-Allerand, C. 
Gee, J. Minna, and F. Alt. 1986. Differential expression of myc 
family  genes  during  murine  development.  Nature  (Lond.). 
319:780. 
9. Jakobovits, A., M. Schwab,  J.M. Bishop, and G. Martin. 1985. 
Expression of N-myc in teratocarcinoma stem cells and mouse 
embryos. Nature (Lond.). 18:188. 
10.  Mugrauer,  G., F. Alt,  and P. Ekblom.  1988. N-myc proto- 
oncogene expression during organogenesis in the developing 
mouse as revealed  by in situ hybridization.J. Cell Biol. 107:1325. 
11.  Hirvonen, H., V. Hukkanen,  T. Salmi, T. M~kelL T.-T. Pel- 
liemi, and IL. Alitalo. 1991. Expression of L- and N-myc proto- 
oncogenes in a subset of human leukemias and leukemia cell 
lines. Blood. In press. 
12.  Land, H. Parada, L., and R.. Weinberg.  1983. Tumorigenic 
conversion of primary embryo fibroblasts requires at least two 
cooperating  oncogenes. Nature (Lond.). 304:596. 
13.  Schwab,  M., H. Varmus, andJ.M. Bishop. 1985. Human N-myc 
gene contributes to neoplastic transformation  of mammalian 
cells in culture. Nature (Lond.). 316:160. 
14.  Yancopoulos, G., P. Nisen, A. Tesfaye,  N. Kohl, M. Goldfarb, 
and F. Alt. 1985. N-myc can cooperate with ras to transform 
normal cells in culture. Proa Natl.  Acad. Sci. USA.  82:5455. 
15.  Small, M., N. Hay, M. Schwab, andJ.M. Bishop. 1987. Neo- 
plastic transformation by the human N-myc gene. Mol. Cell. 
Biol. 7:1638. 
16.  Birrer, M., J. Segal, F. DeGreve, E. Kaye, A. Sausville, and 
J. Minna.  1988. L-myc  cooperates with ras to transform pri- 
mary rat embryo fibroblasts. Mol.  Ceil. Biol. 8:2668. 
17.  Alt, F., R. DePinho, K. Zimmerman, E. Legouy, K. Hatton, 
P. Ferrier, A.  Tesfaye, G. Yancopoulos, and P. Nisen.  1986. 
The human myc gene family. Cold Spring Harbor Symt  x Quant. 
Biol. 51:931. 
18.  Schwab, M.,  K. Alitalo, L. Klempnauer, H. Varmus, J.M. 
Bishop, F. Gilbert,  G. Brodeur, M. Goldstein, and J. Trent. 
1983. Amplified DNA with limited homology to myc cellular 
oncogene is shared by human neuroblastoma cell lines and a 
neuroblastoma tumor. Nature (Lond.). 305:245. 
19.  Lee, W., A.L. Murphee, and W. Benedict. 1984. Expression 
and amplification of  the N-myc gene in human neuroblastomas 
and related tumors.  Nature (Lond.). 309:458. 
20.  Nan, M., B. Brooks,  J. Battey,  E. Sausville,  A. Gazdar, I. Kitsch, 
W. McBride, V. Bertness, G. Hollis, andJ. Minna. 1985. bmyc 
a new myc related gene amplified  and expressed  in human small 
cell lung cancer. Nature (Lond.). 318:69. 
21.  Nisen, P., K. Zimmerman,  S. Cotter, F. Gilbert, and F. Alt. 
1986. Enhanced expression  of  the N-myc gene in Wilms tumor. 
Cancer Res. 46:6217. 
22.  Dolcetti, R., S. Rizzo, A. Viel, R. Maestro, V. DeRe, G. Feri- 
otto, and M. Boiocchi. 1989. N-myc activation by proviral in- 
sertion  in  MCF  24J  induced  T-cell lymphomas.  Oncogene. 
4:1009. 
23.  van Lohuizen, M., M. Breuer, and A. Berns. 1989. N-myc is 
frequently activated  by proviral  insertion in MuLV  induced T-ceU 
lymphomas. EMBO (Eur. Mol. Biol. Organ.) J.  8:133. 
24.  Fourel, G., C. Trepo, L. Bougueleret, B. Henglein,  A. Pon- 
zetto, P. Tiollais, and M.A. Buendia. 1990. Frequent activa- 
tion of N-myc genes by hepadnavirus insertion in woodchuck 
liver tumors.  Nature (Lond.). 347:294. 
25.  Adams,  J., A. Harris, C. Pinkert, L. Corcoran, W. Alexander, 
S. Cory, R. Palmiter, and K. Brinster. 1985. The c-myc on- 
cogene driven by the immunoglobulin enhancers induces lym- 
phoid malignancies in transgenic mice. Nature (Lond.). 318:533. 
26.  Suda, Y., S. Aizawa, S. Hirai, T. Inoue, Y. Furuta, M. Suzuki, 
S. Hirohashi, and Y. Ikawa. 1987. Driven by the same Ig en- 
hancer and SV40 T promotor ras induced lung adenomatous 
tumors,  myc induced pre-B cell lymphomas and SV40 large 
T antigen a variety of tumors in transgenic mice. EMBO (Eur. 
Mol. Biol. Organ.) J.  6:4055. 
321  M6r6y  et al. 27.  Schmidt, E., E Pattengale, L. Weir, and E Leder. 1988. Trans- 
genic mice bearing the human c-myc gene activated by an im- 
munoglobulin enhancer: a pre-B cell lymphoma model. Proc. 
Natl.  Acad. Sci. USA.  85:6047. 
28.  Dildrop, R., A. Ma, K. Zimmerman, E. Hsu, A. Tesfaye,  R. 
DePinho, and F. Alt.  1989. Igh enhancer mediated deregula- 
tion of N-myc gene expression in transgenic mice: generation 
of  lymphoid neoplasms that lack c-myc  expression.  EMBO (Eur. 
Mol. Biol. Organ.)  J. 8:1121. 
29.  Rosenbaum, H., E. Webb, J. Adams, S. Cory, and A. Harris. 
1988. N-myc transgene promotes B-lymphoid proliferation, 
elicits lymphomas  and  reveals crossregulation  with  c-myc. 
EMBO (Eur. Mol. Biol. Organ.)  J. 8:749. 
30.  Yukawa, K., H. Kikutani,  T. Inomoto, M.  Uehira, S. Bin, 
K. Akagi, K. Yamamura, and T. Kishimoto. 1989. Strain de- 
pendency of B and T lymphoma development in immunoglob- 
ulin heavy chain enhancer (E#)-rayc transgenic mice. J. Exp. 
Med. 170:711. 
31.  Mrrry, T., P. Fisher, C. Guidos, A. Ma, K. Zimmerman, A. 
Tesfaye, R. DePinho, I. Weissman, and F. Alt.  1990. Igh en- 
hancer deregulated expression  ofbmyc: abnormal T-lymphocyte 
development and T-cell lymphomagenesis. EMBO (Eur. Mol. 
Biol. Organ.)  J.  9:3659. 
32.  Cory, S., andJ. Adams. 1988. Transgenic mice and oncogenes. 
Annu.  Rw. Immunol. 6:25. 
33.  Maniatis, T., S. Fritsch,  and J. Sambrook.  1983. Molecular 
Cloning: A Laboratory Handbook, Cold Spring Harbor Lab- 
oratory, Cold Spring Harbor,  NY. 
34.  Reed, K., and D. Mann. 1985. Rapid transfer of DNA from 
agarose gels to nylon membranes. Nucleic. Acids Res. 13:7202. 
35.  Yancopoulos, G., S.V. Desiderio, M. Paskind, J.F. Kearney, D. 
Baltimore, and F.W. Alt.  1984. Preferential utilization of the 
most Jh proximal Vh segments in pre-B cell lines. Proa Natl. 
Acad. Sci. USA.  82:5455. 
36.  Gough, N.M.,  and O. Bernard.  1981. Sequences of joining 
region genes for immunoglobulin heavy chains and their role 
in generating antibody diversity. Proc. Natl. Acad. Sci. USA. 
78:509. 
37.  Perry, R.P., D.E. Kelley,  C. Coleclough, J.G. Seidman, P. Leder, 
S. Tonegawa, G. Matthyssens, and M. Weigert.  1980. Tran- 
scription of mouse kappa chain genes: implication for allelic 
exclusion. Proc. Natl..4cad.  Sci. USA.  77:1937. 
38.  Malissen, M.,  K. Minard,  S. Mjolsness, M.  Kronenberg, J. 
Governman, T. Hunkapillar, M.B. Prystowsky, Y. Yoshikai, 
E Fitch, T.W. Mak, and L. Hood. 1984. Mouse T-cell  antigen 
receptor: Structure and organization of constant and joining 
gene segments encoding the fl polypeptide. Cell. 37:1101. 
39.  Lewis, S., N. Rosenberg, E Alt, and D. Baltimore. 1982. Con- 
tinuing  kappa gene rearrangement in a cell line transformed 
by Abelson murine  leukemia virus. Cell. 30:807. 
40.  Yancopoulos, G., B. Malynn, and F. Alt.  1988. Developmen- 
tally regulated and strain-specific  expression  of  murine Vh gene 
families. J. Exp. Med. 168:417. 
41.  Spanopolou, E., V. Giguiere, and F. Grosveld. 1988. Transcrip- 
tional unit of the murine Thy-1 gene: differential distribution 
of transcription initiation sites in brain. Mol. Cell. Biol. 8:3847. 
42.  Curran, T., G. Peters, C. Van Beveren, N. Teich, and I. Verma. 
1982. FBJ murine osteosarcoma virus: identification and mo- 
lecular cloning of biologically active proviral DNA. J.  Virol. 
44:674. 
43.  Bender, T.,  and  M.  Kueht.  1986. Murine  proto-oncogene 
mRNA: cDNA sequence  and evidence  for 5'heterogeneity.  Pro~ 
Natl.  Acad. Sci. USA.  83:3205. 
44.  Rothwell, V., and L. Rohrschneider. 1987. Murine fins cDNA 
322 
clones, sequence and retroviral expression. Oncogene Res. 1:311. 
45.  Kincaide, P.W., G. Lee, G. Feruandes, M.A.S. Moore, N. Wil- 
liams, and R.A. Goose. 1979. Abnormalities in clonal B lym- 
phocyte and myeloid progenitors in autoimmune NZB mice. 
Proc. Natl. Acad. Sci. USA.  76:3464. 
46.  Liebermann, D.A., and B. Hoffman-Liebermann. 1989. Pro- 
tooncogene expression and dissection of the myeloid growth 
to differentiation developmental cascade. Oncogene. 4:583. 
47.  Committee of Standardized Genetic Nomenclature for Mice. 
1972. j. Hered. 63:69. 
48.  Klinken, P.S., W.S. Alexander, and J. Adams. 1988. Hemo- 
poietic lineage switch: v-raf oncogene converts E# myc trans- 
genic B-cells into macrophages. Cell. 53:857. 
49.  Shen-Ong,  G.L.C.,  K.L. Holmes,  and  H.C.  Morse. 1987. 
Phorbol ester induced growth arrest of murine myelomono- 
cytic leukemic cells with virus disrupted myb locus is not ac- 
companied by decreased myc and myb expression. Proc. Natl. 
.A_cad. Sci. USA.  84:199. 
50.  Gonda, T.J., and D. Metcalf. 1984. Expression of myc, myb, 
and los proto-oncogenes during the differentiation of a mu- 
rine myeloid leukemia. Nature (Lond.). 310:249. 
51.  Rettenmeier, C.W., and M.F.R.oussel. 1988. Differential pro- 
cessing of CSF-1 precursors encoded by two human cDNAs. 
MoI. Cell. Biol. 8:5026. 
52.  Ma, A., R. Smith, A. Tesfaye, P. Achacoso, R. Dildrop, N. 
Rosenberg, and EW. Alt.  1991. Mechanism of endogenous 
myc downregulation  in E# N-myc tumors.  Mol. Cell. Biol. 
11:440. 
53.  Harris,  A.,  W.  Langdon,  W.  Alexander, I.  Hariharan,  H. 
Rosenbaum, D. Vaux, E. Webb, O. Bernard, M. Crawford, 
H. Abud,  and S. Cory.  1988. Transgenic mouse models for 
hematopoietic  tumorigenesis.  Cu~  Top. Microtn'ol. Immunol. 
141:82. 
54.  Baumbach, W.R., E.J. Keath, and M.D. Cole. 1986. A mouse 
c-myc retrovirus transforms established fibroblast lines in vitro 
and induces monocyte macrophage tumors in vivo.  J.  Virol. 
59:276. 
55.  Banmbach, W.R., E.R. Stanley, and M. Cole.  1987. Induc- 
tion of  clonal monocyte macrophage tumors in vivo by a c-myc 
retrovirus. Rearrangement of the CSF-1 gene as a secondary 
transforming  event. Mol. Cell. Biol. 7:664. 
56.  Weksler, M.E. 1983. In The Biology of Immunological Dis- 
ease. F.J. Dixon and D.W. Fisher, editors. Sinauer Associates, 
Inc., Sunderland, MA.  295-306. 
57.  Borzillo, G., R. Ashmun,  and C. Sherr. 1990. Macrophage 
lineage switching of murine  early pre-B cells: expression of 
transduced fms genes. Mol. Cell. Biol. 10:2703. 
58.  Wiener, E, S. Ohno, J. Spira, N. Haran-Ghera, and G. Klein. 
1978. Cytogenetic mapping of the trisomic segment of chro- 
mosome 15 in murine T-cell  leukemia. Nature (Lond.). 275:658. 
59.  Spira, J., F. Wiener, S. Ohno, and G. Klein. 1979. Is trisomy 
cause or consequence of murine T-cell  leukemia development: 
Studies of Robertsonian translocation mice. Proc. Natl. Acad. 
Sci. USA.  76:6619. 
60.  DeBoth, N.Y., A. Hagemeijer, E.H. Rhijnsburger, M. Vermey, 
E. Van T. Hull,  and E.M.  Smit.  1981. DMSO induced ter- 
minal differentiation and trisomy 15 in myeloid cell lines trans- 
formed by the Rauscher murine leukemia virus. Cell. D~'ffer. 
10:13. 
61.  Selton, G., H.T.  Cuypers, M. Zijlstra, C. Melief, and A. Berns. 
1984. Involvement  of  c-myc  in MuLV  induced T-ceU  lymphomas 
in mice frequency and mechanism of activation. EMBO (Eur. 
Mol. Biol. Organ.)  J. 3:3215. 
Myelomonocytic  Tumors in E/z bmyc Transgenic Mice 